Correction: The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

Article de revue

Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Christel Larbouret, Marie-Alix Poul, Philippe Mondon, Gerry Melino, André Pèlegrin et Thierry Chardès

Oncotarget, Vol.15(1), pp.748-749

11/10/2024

PMID: 39392382

Résumé

Animals

Humans

Mice

Neoplasms - drug therapy

Neoplasms - metabolism

Proteolysis

Receptor, ErbB-3 - immunology

Receptor, ErbB-3 - metabolism

Repressor Proteins - metabolism

Signal Transduction

Ubiquitin-Protein Ligases - metabolism

Ubiquitination

1 Consultations de la notice

Titre: Correction: The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation
Créateurs - sans rôle: Christophe Le Clorennec - Department of Health and Endocrinology, University Magna Graecia of Catanzaro, Catanzaro, Italy
Yassamine Lazrek - Institut Pasteur de Guyane, BP 6010, 97306, Cayenne Cedex, France
Olivier Dubreuil - GamaMabs Pharma SA, Centre Pierre Potier, ONCOPOLE, BP 50624, France
Christel Larbouret - Department of Health and Endocrinology, University Magna Graecia of Catanzaro, Catanzaro, Italy
Marie-Alix Poul - Department of Health and Endocrinology, University Magna Graecia of Catanzaro, Catanzaro, Italy
Philippe Mondon - LFB Biotechnologies, 59000, Lille, France
Gerry Melino - University of Leicester
André Pèlegrin - Department of Health and Endocrinology, University Magna Graecia of Catanzaro, Catanzaro, Italy
Thierry Chardès - Department of Health and Endocrinology, University Magna Graecia of Catanzaro, Catanzaro, Italy
Détails de publication: Oncotarget, Vol.15(1), pp.748-749
Identifiants: 99140058809311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article